Display options
Share it on

Evid Based Complement Alternat Med. 2016;2016:3198249. doi: 10.1155/2016/3198249. Epub 2016 Apr 06.

Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq.

Evidence-based complementary and alternative medicine : eCAM

Qianqian Yang, Lei Gao, Maocan Tao, Zhe Chen, Xiaohong Yang, Yi Cao

Affiliations

  1. Zhejiang Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou 310006, China; College of Agronomy and Plant Protection, Qingdao Agricultural University, Qingdao 266109, China.
  2. Shandong Provincial Research Center for Bioinformatic Engineering and Technique, School of Life Sciences, Shandong University of Technology, 266 West Cunxi Road, Zibo 255049, China.
  3. Zhejiang Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou 310006, China.

PMID: 27143984 PMCID: PMC4837275 DOI: 10.1155/2016/3198249

Abstract

Candida albicans is the major invasive fungal pathogen of humans, causing diseases ranging from superficial mucosal infections to disseminated, systemic infections that are often life-threatening. Resistance of C. albicans to antifungal agents and limited antifungal agents has potentially serious implications for management of infections. As a famous multiherb prescription in China, Huanglian Jiedu Decoction (HLJJD, Orengedokuto in Japan) is efficient against Trichophyton mentagrophytes and C. albicans. But the antifungal mechanism of HLJDD remains unclear. In this study, by using RNA-seq technique, we performed a transcriptomics analysis of gene expression changes for C. albicans under the treatment of HLJDD. A total of 6057 predicted protein-encoding genes were identified. By gene expression analysis, we obtained a total of 735 differentially expressed genes (DEGs), including 700 upregulated genes and 35 downregulated genes. Genes encoding multidrug transporters such as ABC transporter and MFS transporter were identified to be significantly upregulated. Meanwhile, by pathway enrichment analysis, we identified 26 significant pathways, in which pathways of DNA replication and transporter activity were mainly involved. These results might provide insights for the inhibition mechanism of HLJDD against C. albicans.

References

  1. Genome Res. 2010 Oct;20(10):1451-8 - PubMed
  2. Evid Based Complement Alternat Med. 2014;2014:565784 - PubMed
  3. PLoS Genet. 2007 May 25;3(5):e83 - PubMed
  4. Nat Rev Genet. 2009 Jan;10(1):57-63 - PubMed
  5. J Ethnopharmacol. 2011 Apr 12;134(3):911-8 - PubMed
  6. Biol Pharm Bull. 2001 Oct;24(10):1165-70 - PubMed
  7. Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603 - PubMed
  8. PLoS One. 2015 Apr 14;10(4):e0124265 - PubMed
  9. Bioinformatics. 2009 Aug 1;25(15):1966-7 - PubMed
  10. J Ethnopharmacol. 2009 Jul 30;124(3):444-9 - PubMed
  11. PLoS One. 2015 Mar 30;10(3):e0120452 - PubMed
  12. Microbiology. 1997 Feb;143 ( Pt 2):405-16 - PubMed
  13. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Jan;38(1):75-80 - PubMed
  14. Phytother Res. 2012 Jan;26(1):91-100 - PubMed
  15. Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45 - PubMed
  16. Methods. 2001 Dec;25(4):402-8 - PubMed
  17. Clin Microbiol Rev. 1998 Apr;11(2):382-402 - PubMed
  18. Mar Pollut Bull. 2014 Aug 30;85(2):816-23 - PubMed
  19. Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W293-7 - PubMed
  20. Antimicrob Agents Chemother. 2005 Jun;49(6):2226-36 - PubMed
  21. Life Sci. 2002 Sep 20;71(18):2105-17 - PubMed
  22. Phytomedicine. 2014 Apr 15;21(5):615-23 - PubMed
  23. Mol Gen Genet. 1984;198(2):179-82 - PubMed
  24. J Ethnopharmacol. 2011 May 17;135(2):561-8 - PubMed
  25. Antimicrob Agents Chemother. 2002 Jun;46(6):1695-703 - PubMed
  26. Antimicrob Agents Chemother. 2001 Jun;45(6):1660-70 - PubMed
  27. Cancer Lett. 2000 Aug 31;157(1):9-14 - PubMed
  28. Antimicrob Agents Chemother. 2006 Mar;50(3):1096-9 - PubMed
  29. J Antimicrob Chemother. 2014 Jan;69(1):162-7 - PubMed
  30. Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17594-9 - PubMed
  31. Genome Res. 2011 Dec;21(12):2213-23 - PubMed
  32. Biol Pharm Bull. 2008 Dec;31(12 ):2234-6 - PubMed
  33. Antimicrob Agents Chemother. 1997 Jul;41(7):1482-7 - PubMed
  34. J Clin Microbiol. 2003 Dec;41(12):5623-32 - PubMed
  35. Adv Microb Physiol. 2003;47:131-86 - PubMed
  36. Rev Soc Bras Med Trop. 2013 Nov-Dec;46(6):752-8 - PubMed
  37. Appl Microbiol Biotechnol. 2010 Jan;85(4):1105-14 - PubMed
  38. J Gen Microbiol. 1992 Sep;138(9):1901-11 - PubMed
  39. J Ethnopharmacol. 1999 Nov 30;67(3):377-84 - PubMed
  40. Clin Infect Dis. 1994 Feb;18(2):240-2 - PubMed
  41. Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86 - PubMed
  42. J Ethnopharmacol. 2012 Jun 1;141(2):728-35 - PubMed
  43. Biol Pharm Bull. 2005 Feb;28(2):294-8 - PubMed
  44. J Pharm Pharmacol. 1996 Mar;48(3):327-31 - PubMed
  45. Trends Mol Med. 2002 Feb;8(2):76-81 - PubMed
  46. Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4606-11 - PubMed
  47. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):240-8 - PubMed
  48. Biochem Soc Trans. 2005 Dec;33(Pt 6):1451-5 - PubMed

Publication Types